Trial Profile
A 15-week, Phase 2, Double Blind, Randomized, Placebo-controlled, Dose Ranging Study To Investigate The Efficacy, Safety And Tolerability Of Pf-06649751 In Subjects With Motor Fluctuations Due To Parkinson's Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Aug 2022
Price :
$35
*
At a glance
- Drugs Tavapadon (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Pfizer
- 13 Dec 2017 This trial has been completed in Spain, according to European Clinical Trials Database record.
- 20 Nov 2017 Status changed from active, no longer recruiting to discontinued.
- 10 Oct 2017 This trial has been completed in Germany , according to European Clinical Trials Database record.